The possibility of the use of interferon-gamma in Influenza infection

Nikiforov, Vladimir V.; Владимирович, Никифоров Владимир; Сологуб, Т. В.; Васильевна, Сологуб Тамара; Токин, И. И.; Иванович, Токин Иван; Tsvetkov, V. V; Владимирович, Цветков Валерий; Ерофеева, М. К.; Константиновна, Ерофеева Мариана; Zarubaev, Vladimir V.; Викторович, Зарубаев Владимир

doi:10.17816/eid40849

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, our results are consistent with studies performed earlier [30][31][32] and demonstrate considerable reductions of ARVI in adults and the prolonged prevention effect lasting for at least 1 month after the drug course. Thus, we confi rmed those fi ndings and further showed their independency of a volunteer's vaccination status.…”

Section: клиническая иммунологияsupporting

confidence: 93%

See 1 more Smart Citation

Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19

Talyzin¹,

Myasnikov²,

Бернс³

et al. 2022

Immunologiya

View full text Add to dashboard Cite

Государственное бюджетное учреждение здравоохранения «Городская клиническая больница им. М.Е. Жадкевича» Департамента здравоохранения г. Москвы, 121374, г. Москва, Российская Федерация 2 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр терапии и профилактической медицины» Министерства здравоохранения Российской Федерации, 101990, г. Москва, Российская Федерация 3 Академия постдипломного образования Федерального государственного бюджетного учреждения «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства», 125371, г. Москва, Российская Федерация РезюмеВведение. Исследования in vitro показали высокую противовирусную активность экзогенных интерферонов при предварительной обработке клеток. Интерферон-гамма -уникальный иммунный интерферон, который активно экспрессируется у больных острыми респираторными вирусными инфекциями (ОРВИ), предотвращая тяжелое течение инфекции.Цель работы -оценка безопасности и профилак тической эффективности назального интерферона-гамма для защиты от ОРВИ, в том числе от COVID-19.Материал и методы. В исследование были включены 630 взрослых добровольцев с отрицательным результатом ПЦР-теста на SARS-CoV-2, без респираторных симптомов и противопоказаний к применению интерферона-гамма. Участники были рандомизированы (1 : 1) в 2 группы: исследуемая -с применением профилактического курса назального интерферона-гамма, и группа сравнения -без курса профилактики. Всем участникам был выдан дневник для ежедневного мониторинга респираторных симптомов, нежелательных явлений и регистрации применения фармакотерапии.Результаты. Анализ безопасности не выявил различий между группами (р = 1,000). В течение 28 дней в группе сравнения наблюдалась более высокая заболеваемость ОРВИ, в том числе COVID-19 (13 и 3 случая в группе сравнения и в исследуемой группе соответственно). Отношение шансов составило 0,224 [95 % доверительный интервал (ДИ) 0,040-0,826], p = 0,020. Общее количество случаев ОРВИ, в том числе COVID-19, в группе сравнения за 2 мес исследования было 26 (6 в исследуемой группе). Отношение шансов -0, 233 (95 % ДИ 0,077-0,594; p = 0,001). Самый длительный период сохранения респираторных симптомов наблюдался в группе сравнения (7 и 4 дня в группе сравнения и в исследуемой группе соответственно, р = 0,034).Заключение. Назальный интерферон-гамма как средство профилактики способствует снижению заболеваемости ОРВИ, в том числе COVID-19.

show abstract

Section: клиническая иммунологияsupporting

confidence: 93%

“…According to the placebo-controlled randomized study, the incidence during the prophylaxis period and within 1 month after 2 ten-day cycles of drug use was decreased by more than 2 times. Among those who did get sick, a complicated course of infection was observed 2 times less often [30].…”

Section: клиническая иммунологияmentioning

confidence: 98%

Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19

Talyzin¹,

Myasnikov²,

Бернс³

et al. 2022

Immunologiya

View full text Add to dashboard Cite

show abstract

Consensus ‘Interferon therapy for patients with influenza, SARS and COVID19’

Yushchuk

Маев

Vertkin

2021

Medicinskij alfavit

View full text Add to dashboard Cite

According to the who, the share of acute respiratory viral infections (амма? and influenza) accounts for about 90–95% of all infectious diseases; in russia, influenza and arvi take up to 40% of the total duration of official disability, which determines the significance of this pathology. At the same time, the primary contact of the overwhelming majority of patients with suspected arvi and influenza occurs with a therapist or general practitioner of polyclinics. The proposed consensus of experts is intended to systematize the known approaches to the diagnosis, treatment and secondary prevention of influenza, acute respiratory viral infections and community-acquired pneumonia for their use at outpatient clinics. The schemes of using interferon therapy for arvi and influenza are considered in detail.

show abstract

Analysis of Neutrophil Functional Activity in Patients With Chronic Polyposis Rhinosinusitis After Treatment With Interferon Gamma

Aschina

Баранова

Molotilov

et al. 2023

RCLD

View full text Add to dashboard Cite

Chronic polyposis rhinosinusitis (CPRS) is an inflammatory disease of the nose and paranasal sinuses, accompanied by the formation and recurrent growth of polyps. PDRS is an urgent medical problem, because it is difficult to treat and is accompanied by constant exacerbations. The important role of neutrophil granulocytes in the pathogenesis of CPRS has been proved, as they are the first line of defense in response to tissue damage and active participants in the pathological process. There is evidence of successful use of immunocorrectors in the treatment of patients with CPPS, but they are often prescribed without regard to possible pathogenetic mechanisms of the disease. One of the promising immunomodulators of local use is a preparation of human recombinant interferon gamma. It is known that interferon gamma is able to activate neutrophils due to the receptors to this cytokine, which are located on their surface. The aim of the study was to investigate the functional activity of neutrophils in patients with CPPS and the effect of human recombinant interferon gamma on these indicators. Thirty-five patients with CHRS were examined before and after therapy with intranasal interferon gamma. The control group included 30 healthy subjects. Functional activity of neutrophils was studied in whole blood by chemiluminescent method using double stimulation. Patients with CPRS before treatment revealed increased indexes of neutrophils stimulated activity, maximal intensity of cells luminescence, activation coefficient and decreased time of neutrophils output at maximal luminescence. After treatment with intranasal preparation of interferon gamma there was significant decrease of spontaneous and stimulated activity of neutrophils and maximum intensity of cell luminescence. As a result, after the treatment, in patients with CHRS the values of stimulated production of neutrophils and maximum intensity of cell luminescence were reduced to the level of the control group, and the spontaneous activity of neutrophils was even lower than in healthy subjects, while the neutrophils activation factor remained elevated as in patients before therapy. The results obtained testify to normalization of the main indexes of neutrophil functional activity in CHPS patients after treatment with human recombinant interferon gamma.

show abstract

The possibility of the use of interferon-gamma in Influenza infection

Cited by 3 publications

References 0 publications

Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19

Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19

Consensus ‘Interferon therapy for patients with influenza, SARS and COVID19’

Analysis of Neutrophil Functional Activity in Patients With Chronic Polyposis Rhinosinusitis After Treatment With Interferon Gamma

Contact Info

Product

Resources

About